The AdisInsight team have recently celebrated a milestone for their drug pipeline database, R&D Insight, which published its first drug profile twenty years ago.
In 1994, the first drug profile was written by Stephanie Irvine, one of the founding members of the editorial team for a new database being launched by Adis. The profile was based on the drug Benidipine, a calcium antagonist developed by Kyowa Hakko for the treatment of essential hypertension and angina pectoris.
Since the profile was first created, the editorial team have continued to track the progress of the drug, building a twenty-year history of its development, including company agreements, pharmacodynamics data, and reports on adverse events and clinical trials. At present, Benidipine is marketed in Japan, Turkey, China and the Philippines (as Coniel®) and India (as Caritec®).
R&D Insight now contains profiles of over 30,000 drugs and covers drug- and cell-based products worldwide, focusing on those in development by industry, or with industry involvement, where the drug will be regulated as a prescription drug or available only to physicians for administration.
Glenn Whiteside, Product Specialist for R&D Insight at Adis remarks
“Our goal has always been to provide our users with the most relevant, scientifically-sound data on drugs in development, and we are really proud of the product that we have built over the last two decades”.
The database has thousands of users globally from pharmaceutical companies to universities, hospitals to financial institutions. To support their wide range of users, Adis is in the process of developing a new platform for its AdisInsight database content, which is due to be launched in 2015.
Mike Sumner, VP for Adis Product Management & Development at Springer, states
“This is a really exciting time for AdisInsight as we work on a new platform that will bring together all of our content on drugs, trials, deals and safety for the first time. I believe that the new AdisInsight will help our users to carry out their research faster, make greater discoveries and really benefit from the scientific expertise behind each record.”